A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease

Bibliography

• Russell ES. Hereditary anemias of the mouse: A review for geneticists. Adv Genet 1979;20:357-459
   PubMedGoogle Scholar
• McCulloch EA, Siminovitch L, Till JE, et al. The cellular basis of the genetically determined hemopoietic defect in anemic mice of genotype sl/sld Blood 1965;26(4):399-410
   PubMed Web of Science ®Google Scholar
• Copeland NG, Gilbert DJ, Cho BC, et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 1990;63(1):175-83
   PubMed Web of Science ®Google Scholar
• Trentin JJ. Determination of bone marrow stem cell differentiation by stromal hemopoietic inductive microenvironments (HIM). Am J Pathol 1971;65(3):621-8
   PubMed Web of Science ®Google Scholar
• Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63(1):167-74
   PubMed Web of Science ®Google Scholar
• Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl. locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63(1):225-33
   PubMed Web of Science ®Google Scholar
• Curry JL, Trentin JJ, Wolf N. Hemopoietic spleen colony studies. II. erythropoiesis. J Exp Med 1967;125(4):703-20
   PubMed Web of Science ®Google Scholar
• Wolf NS, Trentin JJ. Hemopoietic colony studies. V effect of hemopoietic organ stroma on differentiation of pluripotent stem cells. J Exp Med 1968;127(1):205-14
   PubMed Web of Science ®Google Scholar
• Gerdes AJ, Storb R. The repopulation of irradiated bone marrow by the infusion of stored autologous marrow. Radiology 1970;94(2):441-5
   PubMed Web of Science ®Google Scholar
• Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977;91(3):335-44
   PubMed Web of Science ®Google Scholar
• Gartner S, Kaplan HS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 1980;77(8):4756-9
   PubMed Web of Science ®Google Scholar
• Mayani H, Guilbert LJ, Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. Eur J Haematol 1992;49(5):225-33
   PubMed Web of Science ®Google Scholar
• Greenberger JS. The hematopoietic microenvironment. Crit Rev Oncol Hematol 1991;11(1):65-84
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425(6960):841-6
   PubMed Web of Science ®Google Scholar
• Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425(6960):836-41
   PubMed Web of Science ®Google Scholar
• Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005;105(7):2631-9
   PubMed Web of Science ®Google Scholar
• Visnjic D, Kalajzic Z, Rowe DW, et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004;103(9):3258-64
   PubMed Web of Science ®Google Scholar
• Chabannon C, Torok-Storb B. Stem cell-stromal cell interactions. Curr Top Microbiol Immunol 1992;177:123-136
   PubMed Web of Science ®Google Scholar
• Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978;4(1-2):7-25
   PubMedGoogle Scholar
• Gong JK. Endosteal marrow: a rich source of hematopoietic stem cells. Science 1978;199(4336):1443-5
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Yilmaz OH, Iwashita T, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005;121(7):1109-21
   PubMed Web of Science ®Google Scholar
• Scadden DT. The stem cell niche in health and leukemic disease. Best Pract Res Clin Haematol 2007;20(1):19-27
   PubMed Web of Science ®Google Scholar
• Duhrsen U, Hossfeld DK. Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol 1996;73(2):53-70
   PubMed Web of Science ®Google Scholar
• Podar K, Richardson PG, Hideshima T, et al. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007;20(4):597-612
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, Munshi NC, et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006;42(11):1564-73
   PubMed Web of Science ®Google Scholar
• Bhatia R, McGlave PB, Dewald GW, et al. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages. Blood 1995;85(12):3636-45
   PubMed Web of Science ®Google Scholar
• Simmons PJ, Przepiorka D, Thomas ED, et al. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987;328(6129):429-32
   PubMed Web of Science ®Google Scholar
• Perkins S, Fleischman RA. Hematopoietic microenvironment. Origin, lineage, and transplantability of the stromal cells in long-term bone marrow cultures from chimeric mice. J Clin Invest 1988;81(4):1072-80
   PubMed Web of Science ®Google Scholar
• Lennon JE, Micklem HS. Stromal cells in long-term murine bone marrow culture: FACS studies and origin of stromal cells in radiation chimeras. Exp Hematol 1986;14(4):287-92
   PubMed Web of Science ®Google Scholar
• Laver J, Jhanwar SC, O'Reilly RJ, Castro-Malaspina H. Host origin of the human hematopoietic microenvironment following allogeneic bone marrow transplantation. Blood 1987;70(6):1966-8
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Fracchiolla NS, Mazzeo LM, et al. Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leuk Lymphoma 2005;46(9):1345-51
   PubMed Web of Science ®Google Scholar
• Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81(8):1398-401
   PubMed Web of Science ®Google Scholar
• Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97(5):1427-34
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Cooper S, Li ZH, et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Hematol 1995;62(4):203-15
   PubMed Web of Science ®Google Scholar
• Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002;26(7):677-86
   PubMed Web of Science ®Google Scholar
• Flores-Figueroa E, Arana-Trejo RM, Gutierrez-Espindola G, et al. Mesenchymal stem cells in myelodysplastic syndromes: Phenotypic and cytogenetic characterization. Leuk Res 2005;29(2):215-24
   PubMed Web of Science ®Google Scholar
• Blau O, Hofmann WK, Baldus CD, et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007;35(2):221-9
   PubMed Web of Science ®Google Scholar
• Marcondes AM, Mhyre AJ, Stirewalt DL, et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008;105(8):2865-70
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Chauhan D, et al. Characterization of adhesion molecules on human myeloma cell lines. Blood 1992;80(9):2306-14
   PubMed Web of Science ®Google Scholar
• Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82(12):3712-20
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002;21(37):5673-83
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-47
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20(42):5991-6000
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001;15(12):1950-61
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001;20(33):4519-27
   PubMed Web of Science ®Google Scholar
• Ferlin M, Noraz N, Hertogh C, et al. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000;111(2):626-34
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-76
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89(2):309-19
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95(7):3597-602
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20(3):345-57
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived dickkopf-1 disrupts wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112(1):196-207
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342(17):1255-65
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Wendling F, Vainchenker W. Pathogenesis of myelofibrosis with myeloid metaplasia: insight from mouse models. Best Pract Res Clin Haematol 2006;19(3):399-412
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Komura E, Tulliez M, et al. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100(10):3495-503
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1low mice). Blood 2002;100(4):1123-32
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-β1 in the development of myelofibrosis. Blood 2005;105(9):3493-501
   PubMed Web of Science ®Google Scholar
• Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1997;90(11):4369-83
   PubMed Web of Science ®Google Scholar
• Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2003;101(8):2983-9
   PubMed Web of Science ®Google Scholar
• Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007;35(11):1739-46
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: Clues to the pathophysiology of MDS? Br J Haematol 2008;140(4):444-53
   PubMed Web of Science ®Google Scholar
• Benito AI, Bryant E, Loken MR, et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003;27(5):425-36
   PubMed Web of Science ®Google Scholar
• Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol 2007;86(4):301-5
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001;28(6):577-82
   PubMed Web of Science ®Google Scholar
• Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007;9(Suppl 1):S7
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. Leukemia 2002;16(2):162-4
   PubMed Web of Science ®Google Scholar
• Mayani H, Guilbert LJ, Clark SC, et al. Composition and functional integrity of the in vitro hemopoietic microenvironment in acute myelogenous leukemia: Effect of macrophage colony-stimulating factor. Exp Hematol 1992;20(9):1077-84
   PubMed Web of Science ®Google Scholar
• Mayani H, Guilbert LJ, Janowska-Wieczorek A. Functional characterization of fibroblastic cells in long-term marrow cultures from patients with acute myelogenous leukemia. Leukemia 1993;7(10):1564-9
   PubMed Web of Science ®Google Scholar
• Mayani H. Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Leukemia 1996;10(6):1041-7
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000;37(3-4):405-14
   PubMed Web of Science ®Google Scholar
• Iwata M, Pillai M, Ramakrishnan A, et al. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2007;109(1):85-92
   PubMed Web of Science ®Google Scholar
• Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109(5):625-37
   PubMed Web of Science ®Google Scholar
• McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276(47):43503-8
   PubMed Web of Science ®Google Scholar
• Flores-Figueroa E, Montesinos JJ, Flores-Guzman P, et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 2008;32(9):1407-16
   PubMed Web of Science ®Google Scholar
• Deeg HJ. Marrow stroma in MDS: Culprit or bystander? Leuk Res 2002;26(7):687-8
   PubMed Web of Science ®Google Scholar
• Marsh JC, Harhalakis N, Dowding C, et al. Recurrent graft failure following syngeneic bone marrow transplantation for aplastic anaemia. Bone Marrow Transplant 1989;4(5):581-5
   PubMed Web of Science ®Google Scholar
• Witherspoon RP, Schubach W, Neiman P, et al. Donor cell leukemia developing six years after marrow grafting for acute leukemia. Blood 1985;65(5):1172-4
   PubMed Web of Science ®Google Scholar
• Lawler M, Locasciulli A, Longoni D, et al. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant 2002;29(5):453-456
   PubMed Web of Science ®Google Scholar
• Mc Cann SR, Lawler M, Gardiner N, et al. Donor leukemia following allogeneic bone marrow transplantation. Leukemia 1994;8(Suppl 1):S133-5
   Google Scholar
• Rupec RA, Jundt F, Rebholz B, et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking IκBα. Immunity 2005;22(4):479-91
   PubMed Web of Science ®Google Scholar
• Walkley CR, Shea JM, Sims NA, et al. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 2007;129(6):1081-95
   PubMed Web of Science ®Google Scholar
• Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency. Cell 2007;129(6):1097-110
   PubMed Web of Science ®Google Scholar
• Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39(7-8):1489-99
   PubMed Web of Science ®Google Scholar
• Hanson JA, Gillespie JW, Grover A, et al. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006;98(4):255-61
   PubMed Web of Science ®Google Scholar
• Fiegl H, Millinger S, Goebel G, et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: Association with HER-2/neu status in primary breast cancer. Cancer Res 2006;66(1):29-33
   PubMed Web of Science ®Google Scholar
• Raj K, John A, Ho A, et al. CDKN2B. methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007;21(9):1937-44
   PubMed Web of Science ®Google Scholar
• Yang AS, Doshi KD, Choi SW, et al DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006;66(10):5495-503
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R. Current roles for allogeneic hematopoietic cell transplantation following nonmyeloablative or reduced-intensity conditioning. Clin Adv Hematol Oncol 2005;3(10):799-819
   PubMedGoogle Scholar
• Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006;12(10):1047-55
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108(3):836-46
   PubMed Web of Science ®Google Scholar
• Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: A retrospective analysis. Leukemia 2006;20(1):128-35
   PubMed Web of Science ®Google Scholar